Merck is financing a $1.85 million study being conducted at Texas Tech University to see if lower dosages of its lucrative but controversial cattle growth drug Zilmax could allow the company to reintroduce the product to U.S. and global markets and kick-start sales.
Merck will stop selling Victrelis in the U.S. by the end of this year. The company cites "advances in treatment practices"--namely, the new all-oral drug cocktails offered by Gilead and AbbVie--and the shrinking demand they've caused.
Eli Lilly is buying big into the idea that the latest and greatest cancer therapies can work even better in combination, inking agreements to study its drugs alongside immunotherapies from Merck and Bristol-Myers Squibb.
SAN FRANCISCO-- With Keytruda, Merck has a first-in-class, highly promising cancer treatment that it's already preparing to submit to the FDA for a lucrative label expansion. But the drug wouldn't be where it is today had the pharma giant not jumped on pharma's slim-down bandwagon, CEO Ken Frazier told a group at the JP Morgan Healthcare Conference.
GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.
Merck and partner Sanofi can breathe easy: According to a new study, their blockbuster Gardasil isn't linked to an increased risk of multiple sclerosis.
Good news for Merck: According to a new study, its cash cow vaccine, HPV-blocker Gardasil, isn't linked to an increased risk of multiple sclerosis--or any other similar CNS diseases, for that matter.
The previously suspended Swiss trial of Merck and NewLink's experimental Ebola vaccine is back on, but this time at a lower dose.
Bristol-Myers Squibb is turning to the California Institute for Biomedical Research (Calibr) in San Diego for new fibrosis drug candidates.
New Year, new expectations for Merck & Co. Bernstein Research analyst Tim Anderson predicts an earlier-than-expected expansion for Keytruda, the company's newly approved cancer immunotherapy. And that would mean hundreds of millions in additional 2015 sales, plus an accelerated boost to revenue and earnings for years to come.